Abstract:Katarzyna So&lstrokkiewicz, 1 Izabela Kokot, 1 Violetta Dymicka-Piekarska, 2 Justyna Dorf, 2 Ewa Maria Kratz 1 1 Department of Laboratory Diagnostics, Division of Laboratory Diagnostics, Faculty of Pharmacy, Wroclaw Medical University, Wroclaw, Poland; 2 Department of Clinical Laboratory Diagnostics, Medical University of Bialystok, Bialystok, Poland Correspondence: Ewa Maria Kratz; Katarzyna So&lstrokkiewicz, Email ; Introduction: Immunoglobulin G (IgG) glycosylation affects its effector functions and is essential in many steps of the inflammatory cascade. Therefore, it may be an important parameter for assessing the body's immune response during the course of COVID-19 (Coronavirus disease 2019). Methods: The N- and O-glycosylation of serum IgG in severe COVID-19 patients (n=87), convalescents (n=50), and healthy subjects (n=65) were examined using a modified lectin-ELISA method with specific biotinylated lectins. The obtained data were analyzed using STATISTICA 13.3PL software. Results: We showed significantly higher expression of Lewis x oligosaccharide structures in severe COVID-19 patients than in the other two groups. Moreover, significantly lower expression of Lewis y sugar structures in IgG glycans was observed in the convalescents when compared with COVID-19 patients and healthy subjects. The lowest expression of highly branched N-glycans in cases of severe COVID-19 indicates that the development of the disease is associated with the presence of typical IgG biantennary N-glycans. The lack of significant differences in the expression of Tn antigen in IgG between studied groups and the significantly lower expression of T antigen in convalescents compared to the patients with severe COVID-19 and healthy subjects indicates a decrease in the content of the T antigen in IgG O-glycans in subjects recovered from COVID-19. Substantially higher reactivities of IgG O-glycans with Jacalin observed in COVID-19 patients and convalescents in comparison to the control group were most probably caused by increased expression of core 3 O-glycans in IgG. Conclusion: Severe COVID-19 is accompanied by the expression in serum IgG of sialylated biantennary and highly branched N-glycans, decorated by fucose of Lewis x and Lewis y structures. The higher reactivity of IgG O-glycans with Jacalin in severe COVID-19 patients and convalescents indicates that the disease development and the recovery process are most probably accompanied by increased expression of the core 3 O-glycans. Keywords: serum IgG, glycosylation, SARS-CoV-2, COVID-19, inflammation Coronaviruses most often cause mild to moderate upper-respiratory tract illnesses in humans. Coronavirus disease 2019 (COVID-19) is an infectious disease caused by the SARS-CoV-2 virus (Severe Acute Respiratory Syndrome Coronavirus 2). Like other coronaviruses, SARS-CoV-2 has four structural proteins, known as the S (spike), E (envelope), M (membrane), and N (nucleocapsid) proteins. The N protein holds the RNA genome; together, the S, E, and M proteins create the viral envelope. 1 Patients with SARS-CoV-2 infection can experience a range of clinical manifestations, from no symptoms, a mild infection similar to a cold, through flu-like symptoms, to pneumonia requiring hospitalization until death. 2 In the first few days after infection with SARS-CoV-2, most patients are asymptomatic and may develop mild upper respiratory symptoms and/or systemic flu-like illness. Severe COVID-19 usually develops at least one week after infection, which may suggest a greater role for a dysregulated immune response than a direct viral cytopathic effect. 3 Immunoglobulin G (IgG) constitutes about 75% of human blood serum immunoglobulins, mediating key cellular functions during viral and bacterial infections. In addition to their neutralizing effect, IgG antibodies have the ability to bind to foreign antigens, forming immune complexes (ICs), which can influence the pathogenesis of disease, especially those with an inflammatory background. This is characteristic of some autoimmune and infectious diseases, where the ICs produced cause a hyper-inflammatory reaction that damages host tissues. 4 Glycoproteins' glycosylation plays an essential role in regulating inflammation and immune response in infectious diseases. IgG in its constant domain (Fc) has one biantennary N-linked glycan, which is attached to asparagine 297 (Asn 297), 5,6 composed of a constant core structure containing three mannose residues and four N-acetylglucosamine (GlcNAc) residues, and may contain additional core fucose, as well as bisecting GlcNAc. The branching arms (α-6 and α-3) ma -Abstract Truncated-

Altered IgG glycosylation at COVID‐19 diagnosis predicts disease severity

IgG N-glycome changes during the course of severe COVID-19: An observational study

Proteomics Investigation of Diverse Serological Patterns in COVID-19

Profile of Immunoglobulin G N-Glycome in COVID-19 Patients: A Case-Control Study

The impact of immunoglobulin G N-glycosylation level on COVID-19 outcome: evidence from a Mendelian randomization study

Are Changes in Serum IgG Glycosylation Related to the Severe Course of SARS-CoV-2 Infection and Recovery Process? In Search of New Diagnostic and Prognostic Biomarkers

A unique serum IgG glycosylation signature predicts development of Crohn's disease and is associated with pathogenic antibodies to mannose glycan

Afucosylated IgG characterizes enveloped viral responses and correlates with COVID-19 severity

The Characterization of Disease Severity Associated IgG Subclasses Response in COVID-19 Patients

Total plasma N-glycomic signature of SARS-CoV-2 infection

Altered spike IgG Fc N-linked glycans are associated with hyperinflammatory state in adult COVID and Multisystem Inflammatory Syndrome in Children

COVID-19 neutralizing antibodies predict disease severity and survival

Immunoglobulin genes and severity of COVID-19

Serum Clusterin Concentration and Its Glycosylation Changes as Potential New Diagnostic Markers of SARS-CoV-2 Infection and Recovery Process

Impaired mucosal IgA response in patients with severe COVID-19

Early non-neutralizing, afucosylated antibody responses are associated with COVID-19 severity

Titers of IgG and IgA against SARS-CoV-2 proteins and their association with symptoms in mild COVID-19 infection

The Impact of IgG Fc‐Glycosylation on Disease Dynamics in Primary Sjögren's Disease‐ Insights from the Belgian Sjögren's Syndrome Transition Trial

Iron Related Biomarkers Predict Disease Severity in a Cohort of Portuguese Adult Patients during COVID-19 Acute Infection

Genetic variants regulating the immune response improve the prediction of COVID-19 severity provided by clinical variables

Direct Detection of Glycated Human Serum Albumin and Hyperglycosylated IgG3 in Serum, by MALDI-ToF Mass Spectrometry, as a Predictor of COVID-19 Severity